Emerald BioStructures, the contract research firm in Bainbridge Island, WA, said today it has formed a new collaboration with Boulder, CO-based SomaLogic. The deal calls for Emerald to provide its expertise in determining precise crystal structures of protein targets on cells, so that SomaLogic can make specific “aptamer” drugs, and small molecules, that bind tightly with the chosen target. Financial terms weren’t disclosed. But this is the second notable deal this year for Emerald, following a partnership with Cambridge, MA-based Forma Therapeutics. For more on the intriguing backstory of Emerald, check out this feature story I wrote back in May.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
